Total Payments
$98,961
2024 Payments
$11,275
Companies
9
Transactions
64
Payment Breakdown by Category
Consulting$78,769 (79.6%)
Other$16,859 (17.0%)
Travel$2,140 (2.2%)
Food & Beverage$1,192 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $78,769 | 26 | 79.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,859 | 9 | 17.0% |
| Travel and Lodging | $2,140 | 11 | 2.2% |
| Food and Beverage | $1,192 | 18 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $28,930 | 10 | $0 (2022) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $20,492 | 19 | $0 (2021) |
| ABBVIE INC. | $11,623 | 12 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $10,673 | 8 | $0 (2018) |
| Merck Sharp & Dohme LLC | $10,500 | 7 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $6,280 | 2 | $0 (2023) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $3,990 | 1 | $0 (2022) |
| F. Hoffmann-La Roche AG | $3,320 | 1 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $3,153 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,275 | 2 | ABBVIE INC. ($9,775) |
| 2023 | $12,315 | 16 | Sumitomo Pharma America, Inc. ($6,280) |
| 2022 | $28,806 | 12 | Sunovion Pharmaceuticals Inc. ($16,718) |
| 2021 | $15,497 | 7 | Sunovion Pharmaceuticals Inc. ($12,212) |
| 2020 | $17,961 | 14 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($15,899) |
| 2019 | $2,418 | 4 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($2,418) |
| 2018 | $2,172 | 2 | Otsuka America Pharmaceutical, Inc. ($2,172) |
| 2017 | $8,517 | 7 | Otsuka America Pharmaceutical, Inc. ($8,501) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 2 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/07/2022 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $3,280.00 | General |
| 06/09/2022 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 04/01/2022 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Consulting Fee | Cash or cash equivalent | $3,990.00 | General |
| 01/27/2022 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 01/05/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $3,280.00 | General |
| 12/02/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $526.75 | General |
| 09/09/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| 08/12/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,160.00 | General |
| 07/08/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $3,280.00 | General |
| 07/01/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/07/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,025.00 | General |
| 12/04/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,728.00 | General |
| 11/13/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $351.00 | General |
| 10/23/2020 | Merck Sharp & Dohme Corporation | MK-8189 (Drug) | Consulting Fee | Cash or cash equivalent | $2,062.50 | General |
| Category: NEUROSCIENCE | ||||||
| 02/26/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $10,878.00 | General |
| Category: PSYCHIATRY | ||||||
| 02/26/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $11.31 | General |
| Category: PSYCHIATRY | ||||||
| 02/26/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $11.30 | General |
| Category: PSYCHIATRY | ||||||
| 02/21/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,246.00 | General |
| 02/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | In-kind items and services | $196.66 | General |
| 02/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 02/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 02/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $30.68 | General |
| 02/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $30.68 | General |
| 01/31/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | In-kind items and services | $190.00 | General |
About Dr. Anissa Abi-Dargham, M.D
Dr. Anissa Abi-Dargham, M.D is a Psychiatry healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1376769729.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anissa Abi-Dargham, M.D has received a total of $98,961 in payments from pharmaceutical and medical device companies, with $11,275 received in 2024. These payments were reported across 64 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($78,769).
Ad
Practice Information
- Specialty Psychiatry
- Location New York, NY
- Active Since 04/17/2007
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1376769729
Products in Payments
- REXULTI (Drug) $10,901
- MK-8189 (Drug) $2,063
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in New York
Dr. Manish Zinzuvadia, M.d, M.D
Psychiatry — Payments: $1.3M
Psychiatry $1.3M
Dr. Jianping Chen, M.d, M.D
Psychiatry — Payments: $1.1M
Psychiatry $1.1M
Dr. Ulla Laakso, Md, MD
Psychiatry — Payments: $957,236
Psychiatry $957,236
Dr. Kerry Sulkowicz, M.d, M.D
Psychiatry — Payments: $476,134
Psychiatry $476,134
Dr. Ralph Aquila, M.d, M.D
Psychiatry — Payments: $327,213
Psychiatry $327,213
Dr. Paul Eder, M.d, M.D
Psychiatry — Payments: $278,989
Psychiatry $278,989